According to the consensus statement from an international expert panel on coronary thrombosis, single antiplatelet therapy (SAPT) with a P2Y12 inhibitor should be considered after 1–3 months of DAPT in patients with HBR (clopidogrel is the most studied P2Y12 inhibitor in this setting) or in those without risk factors for bleeding and without high long-term ischemic risk (ticagrelor is the most studied P2Y12 inhibitor in this setting), while SAPT with ASA should be considered after 3–6 months of DAPT, ideally only if the patient is HBR [44]. Here, P2RY12 is linked to deep vein thrombosis.